Prospective Observational Analysis of Circulating Endocan Levels in Patients Presenting With Acute Diverticulitis

Quantify the level of endocan in blood samples collected from patients with acute diverticulitis in the emergency department. Determine if endocan levels are correlated with the severity of diverticulitis according to the WSES classification. Assess whether patients requiring emergency surgical intervention have higher endocan values compared to others.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Diverticulitis Digestive System Diseases Diverticular Diseases Gastroenteritis Gastrointestinal Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Emergency Department IRCCS San Raffaele

Milan, milano, 20132, Italy

Location contact

Luca Ghirardelli, MD

CONTACT

[email protected]

+393282342663

Luca Ghirardelli, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who have signed informed consent
Patients who are affected by acute diverticulitis after clinical evaluation and imaging (i.e. u.s. or CeCT)

Exclusion criteria

Immunosuppressed patients
Patients suffering chronic inflammatory diseases
Patients with concomitant malignancy, cardiac, renal and haepatic failure
History of major vascular surgery (aneurysmectomy)
Pregnant women
Patients participating in other studies that may interfere with the outcome of the intervention.

Treatment and study plan

Primary outcomes

Endocan serum level at admission

Time frame: The serum of the patients enrolled inthe study will be collected within two hours from emergency room registation and tested for ENDOCAN

To evaluate the correlation between blood concentration of endocan and severity of diverticulitis

Secondary outcomes

Predictive value of endocan in determining which patients need emergency surgery

Time frame: Patients will undergo diverticulitis evaluations (per WSES criteria) within 3 hours of Emergency room admission and study enrollment

Concentration of endocan in grade 3-4 WSES compared to grade1-2
Prognostic value of endocan in determining the risk of recurrent diveritculitis

Time frame: From discharge after definitive tretament till 12 months follow-up

Concentration of endocan in patient who develop a recurrence after 1 year follow-up

Sponsors and collaborators

Lead sponsor

IRCCS Ospedale San Raffaele

Other

Registry information

Acronym: DIVENDO

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Jun 18, 2025
Registry last updated: Jun 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed